Southeastern Grocers Plan of Reorganization Confirmed by Court – PR Newswire (press release)

As previously announced, the Plan will decrease overall debt levels by approximately $600 million (including $522 million of debt exchanged for equity in the reorganized Company) and strengthen the Company’s balance sheet, allowing SEG to invest in the business to further support its financial health and long-term success. Anthony Hucker, President and Chief Executive Officer of SEG,…

Proserv Looks to Future as Company Completes Financial Restructuring – Oil & Gas Technology

Through a debt-for-equity exchange and injection of a $50 million investment, the companys two largest lenders – KKR and funds managed by Oaktree Capital Management, L.P. – will become owners of the company.  Proserv emerges substantially debt-free and with a well-capitalised balance sheet, enabling it to provide strong, life-of-field support to its global customers. In…

Proserv Completes Financial Restructuring, CEO Steps Down – Rigzone

by  Rigzone Staff | Monday, May 14, 2018 Proserv completes a financial restructuring, which it says has strengthened its long-term plans. Proserv, a technology-driven energy services company, announced Monday the completion of a financial restructuring, which it said has strengthened its long-term plans. Through a debt-for-equity exchange and injection of a $50 million investment, the…

ATYR PHARMA, INC. – StreetInsider.com

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 10, 2018 Date of Report (Date of earliest event reported) ATYR PHARMA, INC. (Exact name of…

aTyr Pharma Announces First Quarter 2018 Operating Results, Program Prioritization and Corporate Restructuring – GlobeNewswire (press release)

SAN DIEGO, May 14, 2018 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced operating results for the first quarter ended March 31, 2018. The Company also announced a corporate restructuring plan to streamline its operations as it…